April 26, 2019
|
April 30, 2019
|
May 6, 2019
|
January 1, 2017
|
January 1, 2020 (Final data collection date for primary outcome measure)
|
|
- lung metastasis [ Time Frame: 3 year ]
- tumor recurrence [ Time Frame: 3 year ]
|
|
rate of tumor necrosis less than 90% [ Time Frame: 3 year ] the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III(90%)
|
- tumor necrosis less than 90% [ Time Frame: 3 year ]
- the patients request to quit [ Time Frame: 3 year ]
|
Not Provided
|
Not Provided
|
|
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
|
The Efficacy of New Adjuvant Chemotherapy of Osteosarcoma Combined With Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
|
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.
|
Not Provided
|
Interventional
|
Phase 4
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Prevention
|
- Lung Metastases
- Tumor Necrosis
|
Drug: Zoledronic Acid
|
|
Not Provided
|
|
Recruiting
|
150
|
Same as current
|
January 1, 2023
|
January 1, 2020 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Patients with osteosarcoma who were diagnosed with initial pathology and pathology were excluded from lung metastasis or other metastatic lesions by CT and total body emission-computed tomography, and patients with standard chemotherapy were evaluated.
Exclusion Criteria:
- Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease
|
Sexes Eligible for Study: |
All |
|
Child, Adult, Older Adult
|
No
|
Contact: Xiaobo Yan, Dr. |
+8613588153306 |
yanxiaobo82@gmail.com |
|
|
China
|
|
|
NCT03932071
|
ChiCTR-IPR-16008568
|
No
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
Product Manufactured in and Exported from the U.S.: |
Yes |
|
|
Zhaoming Ye, Second Affiliated Hospital, School of Medicine, Zhejiang University
|
Second Affiliated Hospital, School of Medicine, Zhejiang University
|
Not Provided
|
Principal Investigator: |
zhaoming Ye, Prof. |
2nd Affiliated Hospital Of Zhejiang University |
|
Second Affiliated Hospital, School of Medicine, Zhejiang University
|
May 2019
|